ACM

Aisling Capital Management Portfolio holdings

AUM $360M
This Quarter Return
+28.6%
1 Year Return
+114.67%
3 Year Return
+1,171.46%
5 Year Return
+892.24%
10 Year Return
–
AUM
$151M
AUM Growth
+$151M
Cap. Flow
-$3.61M
Cap. Flow %
-2.38%
Top 10 Hldgs %
97.11%
Holding
17
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

1
ACRS icon
Aclaris Therapeutics
ACRS
$3.15M
2
TRML icon
Tourmaline Bio
TRML
$460K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$9.89B
$46.2M 30.53%
6,068,125
– –
VRNA
2
Verona Pharma
VRNA
$9.16B
$34.8M 22.99%
1,332,485
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.41B
$26.1M 17.22%
1,025,000
– –
GLUE icon
4
Monte Rosa Therapeutics
GLUE
$296M
$11.2M 7.4%
1,472,331
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$209M
$6.84M 4.52%
434,455
-200,000
-32% -$3.15M
BMEA icon
6
Biomea Fusion
BMEA
$116M
$6.73M 4.45%
798,757
– –
PSTX
7
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$5.53M 3.65%
1,043,267
– –
NUVB icon
8
Nuvation Bio
NUVB
$1.02B
$4.88M 3.22%
2,541,009
– –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$2.69M 1.78%
2,834,910
– –
OKUR
10
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
$2.06M 1.36%
886,075
– –
SPRB
11
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
$1.32M 0.87%
1,205,511
– –
MRKR icon
12
Marker Therapeutics
MRKR
$12M
$849K 0.56%
3,142,857
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$996M
$761K 0.5%
1,691,151
– –
TECX
14
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
$717K 0.47%
1,009,779
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$421K 0.28%
288,571
– –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$311K 0.21%
387,653
– –
TRML icon
17
Tourmaline Bio
TRML
$601M
– –
-175,000
Closed -$460K